SEATTLE, Feb. 23,
2023 /PRNewswire/ -- CTI BioPharma Corp.
(Nasdaq: CTIC), a commercial biopharmaceutical company focused on
the development and commercialization of novel targeted therapies
for blood-related cancers, today announced that its fourth quarter
and full year 2022 financial results will be reported on
Monday, March 6, 2023, after the
close of the financial markets. Management will host a webcast and
conference call at 4:30 p.m. Eastern
Time to discuss the results and provide a corporate
update.
Registration for the live and archived webcast may be accessed
on the CTI BioPharma website under the Investors & Media
section: Events and Presentations. To participate via telephone,
please register in advance using the link provided in the event
listing. The Company suggests participants log in 15 minutes in
advance of the event.
About CTI BioPharma Corp.
CTI BioPharma is a commercial biopharmaceutical company focused
on the development and commercialization of novel targeted
therapies for blood-related cancers that offer a unique benefit to
patients and their healthcare providers. CTI has one FDA-approved
product, VONJO® (pacritinib) capsules, a JAK2, ACVR1 and IRAK1
inhibitor, that spares JAK1. VONJO is approved for the treatment of
adults with intermediate- or high-risk primary or secondary
(post-polycythemia vera or post-essential thrombocythemia)
myelofibrosis with a platelet count below 50 × 109/L. This
indication is approved under FDA accelerated approval based on
spleen volume reduction. Continued approval for this indication may
be contingent upon verification and description of clinical benefit
in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA
study of VONJO in patients with myelofibrosis and severe
thrombocytopenia as a post-marketing requirement. For more
information, please visit www.ctibiopharma.com.
VONJO® is a registered trademark of CTI BioPharma Corp.
Investor Relations and Media Contacts:
Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-monday-march-6-2023-301753968.html
SOURCE CTI BioPharma Corp.
